BackOKYO Pharma Limited Overview

OKYO Pharma Limited Total Current Liabilities

OKYO Pharma Limited's total current liabilities is $8.6M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$8.64M
6.35% YoYΔ $-585702.00 vs prior year quarter

Peer average

Loading

OKYO Pharma Limited Total Current Liabilities History

Loading

OKYO Pharma Limited vs. peers: Total Current Liabilities Comparison

Loading

OKYO Pharma Limited Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

OKYO Pharma Limited (OKYO) FAQ

The latest total current liabilities for OKYO is $8.6M as of March 2026. That compares with $9.2M in the prior-year period — down 6.3% year over year. Investors often review this figure alongside OKYO Pharma Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, OKYO's total current liabilities moved from $9.2M to $8.6M — a 6.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in OKYO Pharma Limited's operating scale or balance-sheet position.

A total current liabilities figure of $8.6M for OKYO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting OKYO's total current liabilities ($8.6M), review year-over-year change from $9.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack OKYO Pharma Limited's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.